Bimodal effect of advanced glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipids.
Advanced glycation end-products (AGE) are generated by chronic hyperglycaemia and may cause diabetic microvascular complications such as diabetic nephropathy. Many factors influence the development of diabetic nephropathy; however, dysregulation of mesangial cell (MC) proliferation appears to play an early and crucial role. In this study, we investigated the effects of AGE on rat MC proliferation and the involvement of sphingolipids in the AGE response. Results show a bimodal effect of AGE on MC proliferation. Thus, low AGE concentrations (<1 microm) induced a significant increase (+26%) of MC proliferation, whereas higher concentrations (10 microm) markedly reduced it (-24%). In parallel, AGE exerted biphasic effects on neutral ceramidase expression and activity. Low AGE concentrations increased neutral ceramidase activity and expression, whereas high AGE concentrations showed opposite effects. Surprisingly, neutral ceramidase modulation did not result in changes of ceramide levels. However, the AGE (10 microm)-inhibitory effect on MC proliferation was associated with accumulation of sphingosine and was specifically prevented by blocking glucosylceramide synthesis, suggesting that the high AGE concentration effects are mediated by sphingosine and/or glycolipids. On the other hand, treatment of cells with low AGE concentrations led to an increase of sphingosine kinase activity and sphingosine-1-phosphate production that drove the increase of MC proliferation. Interestingly, in glomeruli isolated from streptozotocin-diabetic rats, a time-dependent modulation of ceramidase activity was observed as compared with controls. These results suggest that AGE regulate MC growth by modulating neutral ceramidase and endogenous sphingolipids.
Geoffroy
Karen
K
Diabetic Microangiopathy Research Unit, MERCK Santé/INSERM UMR 585/INSA-Lyon, Bldg. L. Pasteur, 20 Ave. A. Einstein, 69621 Villeurbanne, France.
Wiernsperger
Nicolas
N
Lagarde
Michel
M
El Bawab
Samer
S
D000581:Amidohydrolases / Q000737:chemistry* / Q000378:metabolism; D000818:Animals; D015153:Blotting, Western; D002455:Cell Division; D002478:Cells, Cultured; D055572:Ceramidases; D002851:Chromatography, High Pressure Liquid; D003921:Diabetes Mellitus, Experimental; D019852:Diacylglycerol Kinase / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005786:Gene Expression Regulation; D005920:Glomerular Mesangium / Q000378:metabolism; D005963:Glucosylceramides / Q000378:metabolism; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D008246:Lysophospholipids / Q000378:metabolism; D008297:Male; D008954:Models, Biological; D055576:Neutral Ceramidase; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013107:Sphingolipids / Q000378:metabolism*; D013110:Sphingosine / Q000031:analogs & derivatives / Q000378:metabolism; D013936:Thymidine / Q000378:metabolism; D013997:Time Factors; D000099157:Sphingosine Kinase
D000581:Amidohydrolases; D055572:Ceramidases; D019852:Diacylglycerol Kinase; D005963:Glucosylceramides; D017127:Glycation End Products, Advanced; D008246:Lysophospholipids; D055576:Neutral Ceramidase; D017853:Phosphotransferases (Alcohol Group Acceptor); D013107:Sphingolipids; D013110:Sphingosine; D013936:Thymidine; D000099157:Sphingosine Kinase; C060506:sphingosine 1-phosphate; C526748:Asah2 protein, rat